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Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks † Andrew D. Burrows Metal-organic frameworks (MOFs) are attracting considerable attention due to their potential for permanent porosity, and the consequent applications of this in areas as diverse as hydrogen storage, separations and heterogeneous catalysis. 1 Since the first report, in 2006, that bioactive molecules could be encapsulated within the pores of MOFs and released slowly, 2 there has been an increased focus on using MOFs to control drug delivery. 3 As an alternative to including bioactive molecules as guests within pores of a pre-formed MOF, it is also possible to use this kind of molecule as a component of the framework itself. 4 In this communication, we report our initial studies on the inclusion into MOFs of the iron chelator drug deferiprone (Hdfp), which is used as an oral treatment for haemosiderosis (iron overload) that can occur as a consequence of regular blood transfusions required in the treatment of conditions such as thalassaemia major and haemochromatosis. 9 Deferiprone has high selectivity for Fe 3+ over other cations, and it is used clinically in Europe and Asia as an orally active iron chelator. In addition, deferiprone possesses antioxidant properties protecting against oxidative stress, 10,11 and recently it has been studied for potential application in the treatment of neurodegenerative diseases such as Alzheimer's.
12
Despite its excellent bioavailability, deferiprone is known to have a number of side effects such as neutropenia and gastro-inestinal disorders. Moreover, it is metabolised (ca. 85%) by O-glucuronidation to a biologically inactive, non-iron chelating 3-O-glucuronide conjugate. 13 Methods to reduce O-conjugation in order to reduce excretion are desirable, and incorporation within a framework material provides a potential means of achieving this. We selected zinc-based MOFs for study, since the affinity of deferiprone for zinc(II) is known to be relatively low, 14 and zinc
MOFs generally decompose at low pH, which would be expected to trigger deferiprone release. The reaction of Zn(NO 3 ) 2 Á6H 2 O with 1,4-benzenedicarboxylic acid (H 2 bdc) and Hdfp in DMF at 100 1C for 24 h gave colourless block-shaped crystals, which were identified through single crystal X-ray analysis as [Zn 3 (bdc) 2 (dfp) 2 ]Á2DMF 1. ‡ Compound 1 has a three-dimensional network structure in which infinite zinc SBUs are bridged by the bdc linkers. The SBUs, shown in Fig. 1a , contain two independent zinc centres -Zn(1) lies on an inversion centres and is 6-coordinate, and bonded to four carboxylate and two dfp oxygen atoms, all from different ligands. Zn(2) is 5-coordinate, and bonded to two carboxylate and three dfp oxygen atoms, with one of the dfp ligands bidentate. The geometry of Zn (2) lies between square planar and trigonal bipyramidal (t = 0.59 15 ). Pairs of carboxylate ligands bridge between Zn(1) and Zn(2), whereas dfp, a deprotonated deferiprone, acts as a bidentate ligand on Zn(2), and a monodentate ligand to two Zn(1) centres. The infinite SBUs run along the crystallographic a-axis, and are interconnected by the bdc linkers to generate rhomboidal pores, into which the dfp ligands project (Fig. 1b) . The pores are also occupied by uncoordinated DMF molecules.
Changing the reaction solvent from DMF to water did not afford any MOF products, but changing it to a 5 : 1 mixture of ethanol and water led to colourless rhomboidal crystals that showed a different powder X-ray diffraction (PXRD) pattern to those of 1. On analysis by single crystal X-ray crystallography, this product was identified as [Zn 3 (bdc) 2 
The structure of compound 2 is related to that of 1, with infinite SBUs linked into a three-dimensional network by the bdc ligands. There are, however, subtle differences in the coordination geometries of the metal centres. Instead of pairs of carboxylate groups bridging between Zn(1) and Zn(2), as observed in 1, only one carboxylate does this, and Zn(1), which lies on an inversion centre, maintains a 6-coordinate geometry by bonding to two water molecules. Zn(2) is coordinated to a bidentate carboxylate in addition to a bridging carboxylate, and as a consequence is 6-coordinate. As a result of this coordination, the infinite SBUs are considerably more puckered in 2 than they are in 1 (Fig. 2a) , as witnessed by ZnÁ Á ÁZnÁ Á ÁZn angles of 95.41 (cf. 152.91 for 1). Hydrogen bonds are present between the water hydrogen atoms and both carboxylate and dfp oxygen atoms. Compound 2 exhibits similar rhomboidal pores to those in 1 (Fig. 2b) , though these are flattened, which is consistent with the lack of inclusion of DMF. Use of a mixture of DMF and water as the solvent gave a mixture of 1 and 2, as shown by PXRD.
The successful incorporation of deferiprone into the framework of the MOFs led us to consider the role of the bridging dicarboxylate, and to determine how the presence of functional groups would affect the structure. Consequently, the reaction between Zn(NO 3 ) 2 Á6H 2 O and deferiprone was carried out in the presence of 2-amino-1,4-benzenedicarboxylic acid (H 2 bdc-NH 2 ) and 2,5-dihydroxy-1,4-benzenedicarboxylic acid (H 2 bdc-(OH) 2 ) under similar conditions as those that gave the mixture of 1 and 2.
In the case of H 2 bdc-NH 2 , two types of crystals were again observed in the product, and comparison of the PXRD patterns with those from the mixture of 1 and 2 suggested the products were the analogous compounds [Zn 3 (bdc-NH 2 ) 2 2 SBUs inter-connected into sheets by the dicarboxylate linkers. In the SBUs, Zn(1) and Zn(3) are each coordinated to five oxygen atoms, two from carboxylate groups, two from a bidentate dfp and a water molecule, with coordination geometries close to trigonal bipyramidal (t = 0.75, 0.77) whereas Zn(2), which lies on a two-fold rotation axis, is 6-coordinate, bonding to four carboxylate and two bridging dfp oxygen atoms (Fig. 3a) . The water molecules serve to terminate the SBUs, and prevent aggregation into the infinite SBUs observed for 1-3, though these are linked together through hydrogen bonds. The bdc-(OH) 2 linkers connect the SBUs into two-dimensional sheets (Fig. 3b) , which contain rhomboidal pores into which the dfp ligands project, and the included DMF molecules are accommodated.
The tri-zinc units observed in 5, and in an aggregated form in 1-4, are a commonly observed motif in zinc MOFs, and have been observed in a number of compounds. [16] [17] [18] [19] In these frameworks, the SBU adopts a Zn 3 (O 2 CR) 6 form, with carboxylate groups radiating out from the Zn 3 'spoke' at approximately 601 angles. In 1-5, dfp linkers take the place of two of the carboxylates, so that the four carboxylate groups radiating from the SBU are at angles of 601 and 1201 from each other, which in combination with the linear linkers generates the rhomboidal pores observed. LCMS analyses showed that 1 gave no release of deferiprone on suspension in either DMSO or methanol, and was stable for more than 1 week in the presence of these solvents. Release of deferiprone 
In conclusion, we have demonstrated that following deprotonation, deferiprone can be included as a ligand in zinc metal-organic frameworks, forming both two-and three-dimensional networks. It adopts a bidentate coordination geometry, reducing the connectivity of the SBUs, generating frameworks with rhomboidal pores. Deferiprone can be released from the MOFs by treatment with PBS or acid, with the rate of release affected by the nature of the acid employed. Current studies are aimed at broadening the type of MOF structures that can incorporate deferiprone as a means of controlling their drug release properties, and results will be reported in due course.
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